Suche Biotechwerte mit noch geringer Marktkap. und interesannten Produkten/Datenbanken. - 500 Beiträge pro Seite

[Courtier]

Besten Dank für Informationen !!!

Gruss

Courtier

[Orionis]

Hallo Courtier!

Schau Dir mal Sciclone an. WKN 886644, NASDAQ-Ticker SCLN. Bei nco geringer, jedoch nicht zu geringer Marktkap. sehr gutes Wachstum bei guten Produkten.

Gleiches gilt auch für Genzyme Transgenics 890469 GZTC.

Ich denke, an beiden kannst Du noch viel Freude haben.

Laß die Bio-Bullen tanzen!

[makeyourday]

Eindeutig und 100% Garantie für Kurspotential nach oben:
Genzyme Transgenics WKN 890469 GZTC;

heute +10% in USA!!!

[peppone]

Solltest diesen bericht lesen.Energy BioSystems Corporation Demonstrates Proprietary Gene Shuffling Technology

BusinessWire
Monday February 7 8:04am

THE WOODLANDS, Texas--(BW HealthWire)--Feb. 7, 2000--Energy BioSystems Corporation (Nasdaq:ENBC) announced today that it has completed the demonstration of a new, proprietary gene shuffling technology. Gene shuffling is a powerful method to create millions of new variant genes coding for enzymes with improved properties. The company has successfully applied the technology to its biodesulfurization development efforts and is now exploring opportunities for the technology in areas beyond biorefining including the chemical, pharmaceutical and agricultural biotechnology sectors.

"Difficulties with existing methods to generate genetic diversity prompted us to develop our own technologies," noted Dr. Daniel J. Monticello, vice president of research and development at ENBC. "We`ve successfully used this new gene shuffling technique in our directed evolution program to combine the best properties of related desulfurization enzymes and generate superior strains. Our approach has important advantages over known technologies and has accelerated our development program." Dr. Monticello will be disclosing certain details of the technology and its implications to ENBC`s projects at the IBC "Annual World Congress on Enzyme Technologies 2000" in February ( http://www.ibcusa.com ).

Dr. Peter Policastro, CEO and president of ENBC, indicated that the technology was part of a comprehensive effort to expand the Company`s capabilities. "In 1999, we implemented a strategic initiative to capitalize on our unique genetic capabilities. The demonstration of our proprietary gene shuffling technology creates both new and complementary business opportunities. Our gene shuffling technology has already made a significant impact on our biodesulfurization program. We intend to apply these capabilities to other projects in the ENBC pipeline and to other opportunities as we identify them."

Energy BioSystems Corporation is a biotechnology company applying state-of-the art, proprietary directed evolution techniques to accelerate the development and commercialization of biocatalyst-based processes for petroleum refining, petrochemicals and fine chemicals production. The Company`s primary focus has been development of biocatalytic desulfurization (BDS), a proprietary process involving the use of enzymes to remove sulfur from oil. Additional information about Energy BioSystems is available at the company`s web site: http://www.energybiosystems.com.

This document contains forward-looking statements that are subject to certain risks, uncertainties and assumptions, including but not limited to, the company`s ability to raise additional capital on a timely basis on favorable terms, the development of the company`s proprietary technology, government regulations, competitive technologies, and the company`s ability to control expenditures. Should one or more of such risks and uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated in such forward-looking statements. For a discussion of such risks and assumptions, see "Risk Factors" included in the company`s annual report on Form 10-K for the year ended Dec. 31, 1998.


Contact: Energy BioSystems Corporation, The Woodlands
Paul G. Brown III, 281/364-6140

[Rubelratz]

Schau dir mal die Sangui an.
MK ca. 100 Mio. Geniale Produkte. Töchter in BRD, Asien und Mutter USA. Dieses Jahr Emission von 3 Mio Aktien in Asien. Erster Titelk dort an der Börse. Wechselö vom OTC Board zur Nasdaq. Marktvolumen der Produkte von ca 5-10 Milliarden $ im Jahr ohne nennenswerte Konkurrenz. Release des Glucosesensors 2001-2003. Schau einfach im Board unter Sangui (SGBI) nach. Das Unternehmen hat im Übrigen 13 Produkte von denen einige schon Lizenziert sind.
Wir werden in den Nächsten Tagen mit einer Serie von Analysedaten Beginnen.
1. Vergleich von Pharma-Biotechwerten mit Sangui.
Nur zum Schnuppern eine Kostprobe:
Umsatz Pharma 3. Größtes Pharmaunternehmen der Welt Roche 8,03 Milliarden Jan - Sept 99 ( Ganz 99 ca. 10 Milliarden).
Chance von Sangui 2006
ca. 35% des Marktes des Glucosesensors 350 Mio - 1 Milliarde.
Blutsubstitut 10% des Marktes ca. 1 Milliarde
Hierraus würde eine faire Marktkap in 2005 von 50 Milliarden$ ergeben oder 5000 $. das heißt ein Potential von ca. 4997 $.
Die dargestellten Umsatzgrößen für das Blutsubstitut sind allerdings optimistisch, da das Únternehmen mit einem Release im Jahr 2003-4 rechnet. 10% des Weltmarktes zu erreichen in 2 Jahren geht nur mit großen Partnern, mit denen man schon heute verhandelt.

[JohnC]

Schau Dir Biosource (BIOI 888 686) an. Kennt nur noch einen Weg.